 It is an α2A adrenergic receptor agonist.It was approved for use by the Food and Drug Administration in the United States in 2018.In the United States, the brand name Lucemyra (lofexidine HCl) is approved for the "mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults," for a treatment duration of 14 days.